Drospirenone in HRT?

Drug and Therapeutics Bulletin

Volumn 47, Issue 4, 2009, Pages 41-44

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DROSPIRENONE PLUS ESTRADIOL; ELLESTE DUET CONTI; ESTROGEN; GESTAGEN; KLIOFEM; KLIOVANCE; PLACEBO; PREMIQUE; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; DROSPIRENONE; PROGESTERONE DERIVATIVE;

ABDOMINAL PAIN; ACNE; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; BLOATING; BONE DENSITY; BREAST ENGORGEMENT; BREAST TENDERNESS; BREAST TUMOR; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DRUG CONTRAINDICATION; DRUG COST; DRUG EXCRETION; DRUG SAFETY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HEADACHE; HIRSUTISM; HUMAN; IRRITABILITY; LEG CRAMP; MASTALGIA; MENOPAUSAL SYNDROME; MENTAL INSTABILITY; NAUSEA; NERVOUSNESS; OILY SKIN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SPOTTING; UTERINE CERVIX TUMOR; UTERUS MYOMA; VAGINA BLEEDING; VAGINA DISCHARGE; WATER RETENTION; WEIGHT GAIN; AGED; BLOOD PRESSURE; BODY WEIGHT; DRUG EFFECT; ECONOMICS; FEMALE; HORMONE SUBSTITUTION; METHODOLOGY; MIDDLE AGED; POSTMENOPAUSE;

AGED; ANDROSTENES; BLOOD PRESSURE; BODY WEIGHT; BONE DENSITY; DRUG COSTS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; PROGESTERONE CONGENERS;

EID: 70349582732     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2009.03.0011     Document Type: Review

References (35)

1. Angeliq 1mg/2mg film coated tablets. Summary of product characteristics, UK. Bayer plc, May 2008.
2. Archer DF et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716-27.
3. McKinlay SM et al. The normal menopause transition. Maturitas 1992; 14: 103-15.
4. Hardy R, Kuh D. Social and environmental conditions across the life course and age at menopause in a British birth cohort study. BJOG 2005; 112: 346-54.
5. Foidart JM, Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17α-spirolactone-derived progestogen. Gynecol Endocrinol 2007; 23: 692-9.
6. Schürmann R et al. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7: 189-96.
7. Melby MK et al. Culture and symptom reporting at menopause. Hum Reprod Update 2005; 11: 495-512.
8. Palacios S et al. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 2006; 55: 297-307.
9. Gray S. Clear up your HRT confusion. Hospital Doctor 2005; 24 March; 24-5.
10. Politi MC et al. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008; 23: 1507-13.
11. Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric 2007; 10 (suppl 1): 3-10.
12. Banks E et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 2004; 291: 2212-20.
13. Cauley JA et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729-38.
14. Hlatky MA et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002; 287: 591-7.
15. Mansour D. FAQs in hormone replacement therapy. The Practitioner 2005; 249: 778-82.
16. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
17. Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703-10.
18. Canonico M et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227-31.
19. Chlebowski RT et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289: 3243-53.
20. Hendrix SL et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006: 113: 2425-34.
21. Vickers MR. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335: 239-44.
22. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
23. Medicines for Women's Health Expert Advisory Group (MWHEAG) of the Commission on Human Medicines (CHM). UK Public Assessment Report: Hormone-replacement therapy: safety update [online]. Available: http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2032228. pdf [Accessed 27 March 2009].
24. Foidart JM. Added benefits of drospirenone for compliance. Climacteric 2005; 8 (suppl 3): 28-34.
25. Kongnyuy EJ et al. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database of Systematic Reviews 1999, Issue3. Art. No.: CD001018. DOI: 10.1002/14651858.CD001018. [Last assessed as up-to-date: 01 July 2005].
26. Salpeter SR et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004; 19: 791-804.
27. Medicines and Healthcare products Regulatory Agency. Hormone-replacement therapy: updated advice. Drug Safety Update [online] 2007; 1(2): 2-6. Available: http://www.mhra.gov.uk/MHRA/DrugSafetyUpdate [Accessed 27 March 2009].
28. Naftolin F. Angeliq - hormone replacement therapy with drospirenone. Climacteric 2007; 10 (suppl 1): 1-2.
29. Warming L et al. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004; 7: 103-11.
30. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric 2005; 8 (suppl 3): 4-12.
31. White WB et al. Effects of a new hormone therapy, drospirenone and 17-β-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48: 246-53.
32. White WB. Drospirenone with 17β-estradiol in the postmenopausal woman with hypertension. Climacteric 2007; 10 (suppl 1): 25-31.
33. NHS, 2008. Prescription cost analysis 2007 [online]. The NHS information centre. Available: http://www.ic.nhs.uk/webfiles/publications/ PCA%20publication/PCA%202007%20complete%20V2.pdf [Accessed 27 March 2009].
34. Scottish Medicines Consortium, 2005. Tablets containing 1 mg estradiol and 2 mg drospirenone (Angeliq) (No: 230/05): new product for the indication: prevention of menopausal symptoms [online]. Available: http://www. scottishmedicines.org. uk/smc/2312.html [Accessed 27 March 2009].
35. Scottish Medicines Consortium, 2005. Tablets containing 1 mg estradiol and 2 mg drospirenone (Angeliq) (No:227/05): new product for the indication: prevention of osteoporosis [online]. Available: http://www. scottishmedicines.org.uk/smc/2311. html [Accessed 27 March 2009].